Altuvoct (efanesoctocog alfa) was approved in the U.K. as a treatment for patients with moderate or severe hemophilia A ages ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

The hemophilia market is expected to experience significant growth due to advancements in gene therapy, innovative treatments, and an increasing focus on personalized medicine. Rising awareness and ...

The Ministry of Health and Population and the World Federation of Hemophilia have signed an agreement to provide free medication to patients with hemophilia, a genetic disorder that causes blood ...

Columnist G Shellye Horowitz shares her approach to dating with chronic illness, particularly regarding when to discuss ...

Hemophilia B is a genetic condition that limits your blood’s ability to clot. Without prompt treatment, it can become a life threatening emergency. Creating a plan can help you better manage ...

CSL Limited (OTC:CSLLY) and uniQure Inc (NASDAQ:QURE) announced the four-year results from the pivotal HOPE-B study ...

Using “cure” to refer to “obtaining a normal life” also fits — if you ignore previously lost education, career opportunities ...

Data from the Phase III FRONTIER3 trial found that 98% of caregivers prefer Mim8 for hemophilia A over other treatments.

Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in ...

Alnylam awaits FDA decisions on Amvuttra & Fitusiran next month, poised to boost revenue, profitability, and share growth.

Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III ...